RESUMEN
Nowadays with a lot of diagnostic facilities it is also difficult to find the right diagnose of herpes encephalitis. The aim of this case report was to give an overview about strategies of diagnostic and therapy of the herpes encephalitis.
Asunto(s)
Líquido Cefalorraquídeo/virología , Trastornos de la Conciencia/líquido cefalorraquídeo , Trastornos de la Conciencia/etiología , Encefalitis por Herpes Simple/líquido cefalorraquídeo , Encefalitis por Herpes Simple/diagnóstico , Anciano , Encéfalo/patología , Diagnóstico Diferencial , Imagen de Difusión por Resonancia Magnética , Epilepsia Parcial Compleja/líquido cefalorraquídeo , Epilepsia Parcial Compleja/diagnóstico , Humanos , Masculino , Examen Neurológico , Reacción en Cadena de la Polimerasa , Recurrencia , Estado Epiléptico/líquido cefalorraquídeo , Estado Epiléptico/diagnóstico , Tomografía Computarizada por Rayos XRESUMEN
PURPOSE: Whether status epilepticus of nonconvulsive epileptic seizures is harmful still remains controversial. To investigate this, the presence and/or extent of neuronal damage in patients with absence status epilepticus (ASE) and patients with complex partial status epilepticus (CPSE) was examined and compared. METHODS: Neuron-specific enolase (NSE) in CSF was examined in the patients with ASE and compared with that of the patients having CPSE. Clinical aspects of these patients also were investigated. RESULTS: CSF NSE levels in ASE patients were lower than those of CPSE patients and were considered as the normal values. No clinical symptoms indicated neuronal damage in the ASE patients. CONCLUSIONS: This study suggests that ASE does not induce neuronal damage. Serum NSE is not always correlated to CSF NSE, and determination of serum NSE levels may be an inappropriate method of estimating neuronal damage in some cases of ASE.
Asunto(s)
Daño Encefálico Crónico/diagnóstico , Electroencefalografía , Epilepsia Tipo Ausencia/diagnóstico , Fosfopiruvato Hidratasa/líquido cefalorraquídeo , Estado Epiléptico/diagnóstico , Adolescente , Daño Encefálico Crónico/líquido cefalorraquídeo , Corteza Cerebral/fisiopatología , Niño , Preescolar , Epilepsia Tipo Ausencia/líquido cefalorraquídeo , Epilepsia Parcial Compleja/líquido cefalorraquídeo , Epilepsia Parcial Compleja/diagnóstico , Femenino , Humanos , Masculino , Examen Neurológico , Neuronas/fisiología , Pronóstico , Estado Epiléptico/líquido cefalorraquídeoRESUMEN
The kynurenine pathway metabolites, quinolinic acid (QUIN) and L-kynurenine are convulsants, whereas kynurenic acid (KYNA) is an antagonist of excitatory amino acid receptors. Imbalances in the concentrations of these metabolites have been implicated in the etiology of human seizure disorders. In the present study, L-kynurenine and QUIN concentrations in both cerebrospinal fluid (CSF) and serum were reduced in patients with intractable complex partial seizures (CPS) in both the postictal period (15-75 min after a seizure) and the interictal period (absence of seizure for > 24 h) as compared with neurologically normal control subjects. Linear regression analyses and analysis of covariance showed that the reductions in serum QUIN and L-kynurenine were correlated to blood antiepileptic medication. L-Tryptophan (L-TRP) levels also tended to be lower in both CSF and serum of the seizure patients. CSF KYNA and serum 3-hydroxykynurenine concentrations were not affected in seizure patients, whereas serum levels of KYNA were reduced. 3-Hydroxykynurenine was not detected in the CSF of either control or seizure patients. The results do not support a role for a generalized reduction in KYNA concentrations or an increased ratio of QUIN:KYNA, or increases in CSF L-kynurenine in initiation and maintenance of intractable CPS humans.
Asunto(s)
Epilepsia Parcial Compleja/metabolismo , Ácido Quinurénico/metabolismo , Quinurenina/metabolismo , Ácido Quinolínico/metabolismo , Adolescente , Adulto , Análisis de Varianza , Anticonvulsivantes/sangre , Anticonvulsivantes/uso terapéutico , Encéfalo/enzimología , Electroencefalografía , Epilepsia Parcial Compleja/sangre , Epilepsia Parcial Compleja/líquido cefalorraquídeo , Humanos , Ácido Quinurénico/sangre , Ácido Quinurénico/líquido cefalorraquídeo , Quinurenina/análogos & derivados , Quinurenina/sangre , Quinurenina/líquido cefalorraquídeo , Hígado/enzimología , Persona de Mediana Edad , Ácido Quinolínico/sangre , Ácido Quinolínico/líquido cefalorraquídeo , Análisis de Regresión , Triptófano/sangre , Triptófano/líquido cefalorraquídeo , Triptófano/metabolismo , Triptófano Oxigenasa/metabolismoRESUMEN
We measured lumbar cerebrospinal fluid (CSF) levels of somatostatin, cholecystokinin, neurotensin, atrial natriuretic factor, vasoactive inhibitory peptide, neuropeptide Y, adrenocorticotrophic hormone, corticotropin releasing hormone, beta-endorphin, metenkephalin, cortisol, alanine, glycine, aspartate, glutamate, taurine, and gamma-aminobutyric acid in 25 inpatients with epilepsy at known interictal and postictal times and in 11 neurologically normal volunteers. There were no significant differences between interictal or postictal complex partial seizures (CPS), postictal generalized tonic-clonic seizures (GTC), and control CSF neuropeptide, cortisol, and amino acid (AA) levels. However, there were nonsignificant trends for CSF levels of several neuropeptides to be increased after CPS and GTC as compared with interictal baseline levels. There were significant correlations between levels of certain CSF neuropeptides or (AAs) and serum antiepileptic drug (AED) levels. Several correlations were noted between CSF levels of AAs, including a correlation between the excitatory neurotransmitters aspartate and glutamate identified only after CPS.
Asunto(s)
Aminoácidos/líquido cefalorraquídeo , Epilepsia/líquido cefalorraquídeo , Hidrocortisona/líquido cefalorraquídeo , Neuropéptidos/líquido cefalorraquídeo , Adulto , Ácido Aspártico/líquido cefalorraquídeo , Epilepsia Parcial Compleja/líquido cefalorraquídeo , Epilepsia Tónico-Clónica/líquido cefalorraquídeo , Femenino , Glutamatos/líquido cefalorraquídeo , Ácido Glutámico , Hospitalización , Humanos , Masculino , Persona de Mediana Edad , Ácido gamma-Aminobutírico/líquido cefalorraquídeoRESUMEN
We report long-term clinical, neurochemical, and electrophysiologic data of gamma-vinyl GABA (GVG, vigabatrin) in three groups of patients. GVG was started as add-on therapy for 75 patients with refractory complex partial seizures (group A) and for 36 mentally handicapped patients with severe epilepsy (group B). The third group (C) consisted of 20 patients with carbamazepine (CBZ) monotherapy, in half of whom GVG monotherapy was substituted. After 3 months, 55% of patients in group A and 42% in group B were responders (reduction in seizure frequency greater than 50%). After 6 (group A) and 3 years (group B) of follow-up, 27 and 33% of the patients, respectively, still had good response to GVG. Neurochemical measurements showed a twofold increase in CSF GABA concentrations and minimal or no changes in other neurotransmitter-related parameters. In group C, substitution of GVG as medication tended to normalize the lengthened latencies in somatosensory evoked potentials (SEPs) observed during CBZ treatment.
Asunto(s)
Aminocaproatos/uso terapéutico , Anticonvulsivantes/uso terapéutico , Electroencefalografía/efectos de los fármacos , Epilepsia/tratamiento farmacológico , Adulto , Carbamazepina/uso terapéutico , Quimioterapia Combinada , Epilepsia/líquido cefalorraquídeo , Epilepsia/fisiopatología , Epilepsia Parcial Compleja/líquido cefalorraquídeo , Epilepsia Parcial Compleja/tratamiento farmacológico , Epilepsia Parcial Compleja/fisiopatología , Potenciales Evocados Somatosensoriales/efectos de los fármacos , Femenino , Estudios de Seguimiento , Humanos , Discapacidad Intelectual/complicaciones , Masculino , Monitoreo Fisiológico , Vigabatrin , Ácido gamma-Aminobutírico/líquido cefalorraquídeoRESUMEN
A number of pharmacological evidence supports the view that somatostatin (SS) may be importantly involved in the seizure susceptibility both in humans and in laboratory animals. In a previous report the Authors have provided the finding that a short-term carbamazepine (CBZ) administration is able to reduce SS-CSF-IR in epileptic patients. The present study has been carried out to investigate whether a long-term treatment with CBZ affects in a similar way SS-IR content in CSF from temporal lobe epileptics (CPS). The results confirm and expand previous evidence suggesting that CBZ lowering effect on CSF-SS-IR may be relevant to its anticonvulsivant action.
Asunto(s)
Carbamazepina/farmacología , Epilepsia Parcial Compleja/tratamiento farmacológico , Somatostatina/líquido cefalorraquídeo , Carbamazepina/administración & dosificación , Carbamazepina/uso terapéutico , Líquido Cefalorraquídeo/efectos de los fármacos , Depresión Química , Epilepsia Parcial Compleja/líquido cefalorraquídeo , Femenino , Humanos , Técnicas para Inmunoenzimas , MasculinoRESUMEN
An implanted stimulating device chronically stimulated the left cervical vagus nerve in epileptic patients. Cerebrospinal fluid concentrations of free and total gamma-aminobutyric acid, homovanillic acid, 5-hydroxyindoleacetic acid, aspartate, glutamate, asparagine, serine, glutamine, glycine, phosphoethanolamine, taurine, alanine, tyrosine, ethanolamine, valine, phenylalanine, isoleucine, vasoactive intestinal peptide, beta-endorphin, and somatostatin were measured before and after 2 months of chronic stimulation in six patients. Significant increases were seen in homovanillic acid and 5-hydroxyindoleacetic acid in three patients, and significant decreases in aspartate were seen in five patients. These changes were associated with a decrease in seizure frequency.
Asunto(s)
Aminoácidos/líquido cefalorraquídeo , Aminas Biogénicas/líquido cefalorraquídeo , Epilepsia Parcial Compleja/fisiopatología , Hormonas/líquido cefalorraquídeo , Nervio Vago/fisiopatología , Adulto , Estimulación Eléctrica , Epilepsia Parcial Compleja/líquido cefalorraquídeo , Humanos , Persona de Mediana EdadAsunto(s)
Química Encefálica , Epilepsia Parcial Compleja/metabolismo , Ácidos Quinolínicos/análisis , Anticonvulsivantes/uso terapéutico , Resistencia a Medicamentos , Epilepsia Parcial Compleja/líquido cefalorraquídeo , Epilepsia Parcial Compleja/tratamiento farmacológico , Humanos , Ácido Quinolínico , Ácidos Quinolínicos/líquido cefalorraquídeoRESUMEN
Ten patients, suffering from drug-resistant complex partial seizures were treated for a period of up to 3 years with vigabatrin (Sabril). Vigabatrin is a novel antiepileptic agent, whose action is based on the inhibition of gamma-aminobutyric acid (GABA) aminotransferase, the enzyme responsible for the catabolism of the neurotransmitter GABA. Samples of lumbar cerebrospinal fluid were obtained from the patients prior to commencing vigabatrin therapy, and thereafter at 6 months, 1 year, 2 years, and up to 3 years following the initiation of vigabatrin treatment. The influence of vigabatrin on the cerebrospinal fluid concentrations of free and total GABA, homocarnosine, homovanillic acid, 5-hydroxyindoleacetic acid, and 3-methoxy-4-hydroxyphenylethylene glycol, as well as of the drug itself, was assessed. All patients demonstrated a clinical response to vigabatrin, and the drug was well tolerated over the entire observation period. Mean (+/- SD) reduction of seizure frequency was 65% +/- 23% (range, 26% to 100%) when comparing the end of the treatment period to the previgabatrin baseline. The cerebrospinal fluid concentrations of both free and total GABA and of the dipeptide homocarnosine showed approximately 2- to 5-fold increases over baseline values, with free GABA and homocarnosine being the more sensitive variables. Cerebrospinal fluid concentrations of homovanillic acid, 5-hydroxyindoleacetic acid, and 3-methoxy-4-hydroxyphenylethylene glycol were not altered in a significant manner over the observation period. These findings support the concept that the effects of vigabatrin are restricted to an effect on GABA catabolism and do not extend to the neurotransmitters dopamine and norepinephrine. Clinical efficacy and elevation of GABA and homocarnosine concentration were sustained over the period of observation.